22920-31-6

Basic information

• Product Name: Naphthalene, 1-[(1E)-2-(4-methoxyphenyl)ethenyl]-
• CAS NO: 22920-31-6
• Molecular Formula: C19H16O
• Molecular Weight: 260.335
• Mol File: 22920-31-6.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Naphthalene, 1-[(1E)-2-(4-methoxyphenyl)ethenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Naphthalene, 1-[(1E)-2-(4-methoxyphenyl)ethenyl]-(22920-31-6)
• EPA Substance Registry System: Naphthalene, 1-[(1E)-2-(4-methoxyphenyl)ethenyl]-(22920-31-6)

Safety Data

• Hazardous Substances Data: 22920-31-6(Hazardous Substances Data)

Upstream product

• 90-12-0 1-Methylnaphthalene 
• 836-41-9 p-methoxybenzylidene-phenylamine 
• 637-69-4 4-Methoxystyrene 
• 28912-93-8 1-naphthyldiazonium tetrafluoroborate 
• 1145-93-3 diethyl 4-methoxybenzylphosphonate 
• 66-77-3 1-naphthaldehyde 
• 90-11-9 1-Bromonaphthalene 
• 1613-96-3 N-(4-methoxybenzylidene)aniline 
• 18410-58-7 1-<(trimethylsilyl)methyl>naphthalene 
• 123-11-5 4-methoxy-benzaldehyde 
• 2746-25-0 p-Methoxybenzyl bromide 
• 21960-26-9 (4-methoxybenzylidene)triphenylphosphorane 
• 71426-20-5 1-methoxy-4-((phenylsulfinyl)methyl)benzene 

Relevant articles and documents

Olefination of N-Sulfinylimines under Mild Conditions

A very simple and efficient diastereoselective synthesis of 1,2-disubstituted alkenes has been achieved under mild conditions. Sulfoxide stabilised N-sulfinylimines reacted with in-situ-generated phosphonate carbanions to give 1,2-disubtituted alkenes in good to excellent yields. Different aryl phosphonates reacted with a range of electronically diverse N-sulfinylimines to give alkenes with >99:1 E selectivity. The most important feature of this protocol is that the reaction can be carried out at room temperature with inexpensive sodium hydride as the most effective base to generate the reactive phosphonate carbanions, and producing the alkenes with E selectivity in up to 85 % isolated yield.

THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS

The present invention relates to method(s) of treating a subject afflicted with a skin disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans- stilbene or a stilbene hybrid. A method of treating or reducing the likelihood of a skin disease or condition in a patient is an additional embodiment of the present invention. Preferred pharmaceutical compositions of the invention include nanoemulsions comprising a therapeutically effective amount of a substituted cis or trans-stilbene or stilbene hybrid and at least one antibiotic.

Substituted CIS- and trans-stilbenes as therapeutic agents

The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.